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Abstract
Background: Management of head and neck cancers (HNC) in radiation
oncology in the coronavirus disease 2019 (COVID-19) era is challenging. Aim
of our work is to report organization strategies at a radiation therapy (RT)
department in the first European area experiencing the COVID-19 pandemic.
Methods: We focused on (a) dedicated procedures for HNC, (b) RT schedul-
ing, and (c) health care professionals' protection applied during the COVID-19
breakdown (from March 1, 2020 to April 30, 2020).
Results: Applied procedures are reported and discussed. Forty-three patients
were treated. Image-guided, intensity modulated RT was performed in all
cases. Median overall treatment time was 50 (interquartile range: 47-54.25)
days. RT was interrupted/delayed in seven patients (16%) for suspected
COVID-19 infection. Two health professionals managing HNC patients were
proven as COVID-19 positive.
Conclusion: Adequate and well-timed organization allowed for the optimiza-
tion of HNC patients balancing at the best of our possibilities patients' care
and personnel's safety.
KEYWORD S
COVID-19, departmental procedures, head and neck cancer, health care protections, radiation
oncology
1 | INTRODUCTION
Since the February 20, 2020, Italy is experiencing one
of the most severe coronavirus disease 2019 (COVID-
19) outbreak worldwide, with the region of Lombardy
being the first area in Europe hit by the pandemic. At
present, Lombardy is the most affected areas in Italy,
with 15 116 deaths and 82 904 cases as of May 12,
2020. Of these, 21 632 were diagnosed in the Milan
area. Therefore, health care services across the Region
are still facing and unprecedented challenges in
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limiting transmission rates in order to guarantee the
continuity of care.1
Patients with cancer are often frail and immunocom-
promised, and therefore at risk of being more severely
affected by COVID-19 infection.2,3 Following the
Regional resolution XI-2906 approved on the eighth of
March 2020, selected centers were designated as oncolog-
ical hubs, meaning that they were called to host patients
from hospitals in the frontline for COVID-19 emergency.
Since our Institution was included among Lombardy
oncological hubs, a set of procedures were implemented
in order to guarantee a safe care and working
environment.
Several reports and recommendations have been pub-
lished on the management of head and neck cancer
(HNC) from both an ethical and surgical perspective.4-6
Moreover, a recent consensus by the American and Euro-
pean Societies of Radiation Oncology (ASTRO and
ESTRO, respectively) was published to provide guidelines
on optimal radiation therapy (RT) strategies during the
pandemic.7 Nevertheless, issues related to the manage-
ment of HNC patients during RT have not been reported
yet. Hence, aim of the current work is to report on tech-
nical aspects and the organization strategies applied in a
radiation oncology facility operating in the first European
area hit by the COVID-19 pandemic. As fourth of May
represents the end of the lockdown phase in Italy, we
wish to share our experience, and to provide some high-
lights on how everyday activities were reorganized to face
an evolving epidemiological scenario, together with the
short-term results of our efforts.
1.1 | Peculiarities of HNC clinical
management
With a number of incident and prevalent cases in Lom-
bardy of 1583 and 2687 in 2019, respectively, HNCs can
be considered as relatively rare. Nevertheless, a recent
national Italian survey among Radiation Oncology facili-
ties has shown that the majority of COVID-19 positive
oncological patients had a diagnosis of either lung or
HNCs and had their domicile in Lombardy.1
For the radiation oncologist, HNC patients in the
COVID-era8 the following peculiarities should be consid-
ered: (a) HNC are non-deferrable treatments,9,10 (b)
increase in overall treatment time (OTT) negatively
affects survival in curative-intent treatments,5,6 (c)
patients are generally elderly, heavy smokers as well as
affected by several comorbidities,11-13 (d) as curative-
intent RT is administrated in 25-35 fractions, patients are
required to perform multiple hospital accesses, which
may increases their risk of contagion,7 (e) the need of
removing patient's surgical masks in different phases of
RT favors environmental dissemination of droplets,5 (f)
the frequent presence of a tracheostomy represents a fur-
ther mean of viral spreading,14 (g) abundant mucous
secretions with cough secondary to tumor- and treat-
ment-related distress might further favor cross-infections,
(h) high risk of developing ab-ingestis pneumonitis as a
consequence of tumor and/or treatment-related
swallowing impairment could make patients prone to
pulmonary distress syndromes,15 and (i) the combined
effect of RT and concomitant systemic treatments
(mainly platinum-based chemotherapy) could result in
myelosuppression, thus favoring infectious disease.16
2 | MATERIALS AND METHODS
Data of HNC patients treated with RT at the Radiation
Oncology Department of the European Institute of
Oncology IRCSS (Milan, Italy) were reviewed. The con-
sidered time frame encompassed the early phase of
COVID-19 pandemic in Lombardy (March 1, 2020 to
April 30, 2020). The impact of the pandemic was ana-
lyzed as: (a) dedicated departmental procedures for HNC,
(b) treatment scheduling (ie, delays, interruptions), and
(c) health care professionals' protection was analyzed. As
the current report focuses on outpatients treated with
external beam RT, hospitalization and brachytherapy-
related procedures are not described. Medical records
from HNC patients were retrieved from electronic medi-
cal charts. This work was approved by the Ethical Com-
mittee of the European Institute of Oncology IRCSS
(notification number IEO726). All patients signed a writ-
ten informed consent for clinical research purposes.
3 | RESULTS
3.1 | Radiation Oncology Department—
general organization
Eighteen radiation oncologists, 15 radiation oncology res-
idents, 11 medical physicists, 25 radiation therapists, and
six nurses are currently working at our department. On
average, the number of outpatient treatments is approxi-
mately 900 per week. In this time of emergency, and
given the role of oncological hub, our efforts were
directed toward maintaining an efficient clinical routine.
For this reason, the entire workflow was reorganized
to minimize COVID-19 transmission among both the per-
sonnel and the patients. All measures were coordinated
by a COVID-19 emergency team composed by the chief
of the department, three senior radiation oncologists, the
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radiation therapist coordinator, the nursing coordinator,
and the chief of the medical physics unit, in compliance
with the institutional recommendations.
The health care personnel were assigned a COVID-19
exposure risk class. Personal protective equipment (PPE)
was provided accordingly: (a) low-risk of COVID-19
exposure (surgical mask, disposable gloves), (b) interme-
diate risk of COVID-19 exposure (surgical masks, dispos-
able gloves, disposable gowns, medical caps), and (c)
high risk of COVID-19 exposure (filtering facepieces—
FFP2/KN95 and FFP3 masks, disposable gloves, dispos-
able gowns, medical caps, goggles or face shield, aprons).
The administrative staff and the medical physicists were
assigned to the first group, the health care professionals
(namely, physicians, radiation therapists, and nurses)
without contacts with HNC patients to the second group,
and the health care professionals with contacts with
HNC patients to the third group. All staff members were
required to use PPE for the whole working day, regard-
less of whether their activity encompassed any direct con-
tact with patients.
A full list of the policies for the whole department is
provided in Supporting Information.
TABLE 1 Procedures developed at our department for patients with head and neck cancer
First outpatient
evaluation
– As all patients were considered as potential COVID-19 asymptomatic carriers, medical doctors were
equipped accordinglya
– Clinical history on COVID-19-related symptoms was collected
– Any strict contact with COVID-19-positive cases was recorded
– Any swallowing and/or respiratory defect which could exacerbate cough and mucous secretion were
minimized
– Any swallowing and/or respiratory deficiency which could increase the risk of ab-ingestis pneumonia was
considered
–Medical beds and room equipment were cleaned with alcohol-based disinfectants after each consultation
Simulation CT – All simulation CT were scheduled on a dedicated day
– As all patients were considered as potential COVID-19 asymptomatic carriers, medical doctors and radiation
therapists were equipped accordinglya
– Thermoplastic masks and mouthpiece assisted bites were cleaned with alcohol-based disinfectants after
each use
– CT couches and set-up devices were cleaned with alcohol-based disinfectants following every treatment
RT treatment session – All treatment sessions of HNC patients were scheduled in the morning
– As all patients were considered as potential COVID-19 asymptomatic carriers, radiation therapists were
equipped accordinglya
– Treatment couches and set-up devices were cleaned with alcohol-based disinfectants after each treatment
session
– Thermoplastic masks and bite were sanitized with alcohol-based disinfectants after each treatment session
Clinical evaluation
during RT
– Patients received a complete oral cavity and oropharyngeal examination at least once per week to assess
acute RT-related toxicities
– A dedicated consultation room was assigned to HNC patients, and sanitized at the end of each day
– As all patients were considered as potential COVID-19 asymptomatic carriers, medical doctors and radiation
therapists were equipped accordinglya
–Medical beds and room equipment were cleaned with alcohol-based disinfectants after each consultation
Nursing care – As all patients were considered as potential COVID-19 asymptomatic carriers, nurses and radiation
therapists were equipped accordinglya
– Skin medication requiring the removal of patients' surgical mask were performed only if strictly necessary
– Patients were instructed to perform skin medication by themselves in order to minimize the risk of viral
dissemination in the infirmary
– In case of medication requiring the removal of the surgical mask, access to the infirmary was not allowed to
any other patient
–Medical beds and room equipment were cleaned with alcohol-based disinfectants after each procedure
requiring the mask removal
Follow-up – Telehealth surveillance was organized by phone to verify clinical status and results of prescribed radiological
examinations
Abbreviations: CT, computed tomography; HNC, head and neck cancer; RT, radiotherapy.
aPersonal protection equipment for health professionals managing HNC patients were: filtering facepieces-FFP2/KN95 and FFP3 masks, dis-
posable gloves, disposable gowns, medical caps, goggles or a face shield, aprons.
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3.2 | Departmental COVID-19 dedicated
procedures
Treatment scheduling was not modified and was
followed our institutional clinical practice: 6 weeks after
surgery, 4 weeks after the last cycle of induction chemo-
therapy, within 4 weeks for exclusive radiation or concur-
rent chemoradiation.
The whole care path for HNC patients was re-planned
according to temporal and special criteria, with the aim
to maintain a safe working and treating environment. As
previously detailed, patients were required to wear a sur-
gical mask unless otherwise instructed by the personnel.
A second surgical mask was provided to cover tracheoto-
mies, if needed. A summary of dedicated procedures for
HNC patients is provided in Table 1.
Time management in the COVID-19 pandemic
encompassed scheduling all computed tomography simu-
lation scans and RT delivery in dedicated slots. The ratio-
nale beyond these measures was to optimize room
sanitization and to easily provide all involved health care
professionals with PPE.
All treatments are performed with mouthpiece-
assisted head and shoulder thermoplastics masks
(FirmFit Thermoplastics Masks CIVCO Radiotherapy
Corporate Office 2303, Iowa, United States of America),
to minimize intrafraction and interfraction movements
during treatment delivery. Due to our immobilization
device of choice, it was not possible for patients to keep
surgical masks during RT delivery. For safety reasons,
patients were instructed to wear their surgical mask until
they were correctly positioned on treatment couch. Sub-
sequently, they were invited to remove the surgical mask
and to insert their personalized mouth bites. The thermo-
plastic mask could therefore be applied by the radiation
therapist, who performed the standard set-up procedures.
The temporary removal of surgical masks by the radia-
tion therapist managing HNC patients' set-up procedures
were considered as a potential source of contamination,
and an adequate PPE was provided accordingly
(Figure 1).
Similarly, patients' surgical masks were removed at
least once per week during medical consultations for oral
cavity examination and toxicity assessment. A consulta-
tion room was reserved exclusively for HNC patients, and
sanitized at the end of every working day. Clinical evalu-
ations during the RT treatment were regularly performed.
Follow-up consultations were organized according to the
general department procedures detailed in Supporting
Information. In detail, follow-up evaluations for HNC
patients were organized in the form of telehealth surveil-
lances, except for those requiring a physical and radio-
logic assessment of their gross tumor volume response
following a curative-intent RT. In order to limit the
FIGURE 1 A, Surgical mask in place during the first phase of positioning on treatment couch. B, Detail of mouthpiece bite. C,
Mouthpiece bite in place. D, Thermoplastic mask in place. E, Self-protection equipment for all health care professionals managing head and
neck cancer patients [Color figure can be viewed at wileyonlinelibrary.com]
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accesses to our Institute, patients with no evidence of dis-
ease and good performance status were invited to stay at
home and to reschedule their consultations.
All the above-mentioned procedures were progres-
sively implemented according to pandemic development
and in accordance with World Health Organization
(WHO), National and recommendations and availability
of Institutional resources.17 While COVID-19 phase II
started in Italy on May 4, 2020, these procedures are still
applied in our department while this work is being writ-
ten (10th of March).
3.3 | Impact of COVID-pandemic on
HNC patients
Forty-three patients were included in the analysis. Dur-
ing the first 2 months of the COVID19 pandemic a
slightly higher number of patients were treated at our
department as compared with the same period of 2019
(44 vs 36, respectively, +22%). This could be probably
explained by the fact that as a hub center, some patients
were referred from other Institutions. All patients
received image-guided intensity modulated volumetric
arch therapy (VMAT). Two patients maintained their tra-
cheostomy positioned at time of surgery. Patients' and
treatment characteristics are provided in Table 2.
Postoperative RT was started after a median time of
58 (interquartile range [IQR] 53-69) days for the 17
patients treated with surgery. Exclusive RT was initiated
after a median time of 29 (IQR 20-42) days following the
first clinical examination performed by the radiation
oncologist (22 patients). For the four patients who had
undergone induction chemotherapy, a median time to
RT start was 24 (IQR 14-30) days from the last cycle.
Median OTT was 50 (IQR: 47-54.25) days. Overall, RT
was interrupted/delayed in seven patients (16%) as a con-
sequence of a suspected COVID-19 infection. Specifically:
– One patient presenting with fever was diagnosed with
COVID-19-related pneumonia on fourth of March after
TABLE 2 Patients-related, tumor-related, and treatment-
related characteristics
Total number of patients: 43 n (%)
Patients' characteristics
Gender
Male 30 (70)
Female 13 (30)
Median age (IQR), years 65 (57-74)
Patients' region of origin
Lombardy 24 (55)
Other regions 19 (45)
Comorbidities
Cardiovascular 17 (40)
COPD 10 (23)
Smoking status
Active 12 (28)
Former 22 (51)
Never 9 (21)
Alcohol abuse
Active 3 (7)
Former 1 (2)
Never 39 (91)
Tumor characteristics
Disease subsite
Oropharynx 13 (30)
Larynx 8 (19)
Oral cavity 5 (13)
Nasopharynx 5 (13)
Nasal cavity/paranasal sinuses 4 (9)
Salivary glands 2 (4)
Hypopharynx 2 (4)
Unknown primary 1 (2)
Other 3 (6)
Stage (per TNM 8th edition)
I 3 (6)
II 5 (13)
III 11 (26)
IV 24 (55)
Treatment characteristics
Radiation treatment setting
Exclusive 25 (58)
Adjuvant 17 (40)
Palliative 1 (2)
Systemic therapy
Yes 23 (54)
(Continues)
TABLE 2 (Continued)
Total number of patients: 43 n (%)
Induction + concomitant 4
Concomitant platinum-based CT 15
Anti-EGFR 4
No 20 (45)
Abbreviations: COPD, chronic obstructive pulmonary disease; CT,
computed tomography; EGFR, anti-epidermal growth factor; IQR,
interquartile range; TNM, tumor node metastasis (per American
Joint Committee on Cancer).
ALTERIO ET AL. 5
receiving 18 Gy out of the prescription dose of 70 Gy for
cT1cN2M0 HPV-positive oropharyngeal cancer, TNM
eighth edition.18 The patient required hospitalization for
intensive respiratory distress of COVID-19 related pneu-
monitis and was treated at an intensive care unit of a
dedicated COVID-19 hospital. After a quarantine period,
the patient was proven negative at two consecutive nasal
swabs (seventh of April). Due to a prolonged interruption
of 57 days, after multidisciplinary discussion, a salvage
surgery ± postoperative RT according to pathology speci-
men findings was proposed.
– Four patients had their RT interrupted following the
onset fever. Nasal swabs tests were negative in all cases.
RT breaks was 2 days for all patients.
– One patient interrupted curative RT for 23 days due to
the quarantine measurements of her residence area.
Treatment was interrupted at the dose of 62 Gy. OTT
time was 105 days (further interruptions were needed for
severe skin RT-induced toxicity).
– One patient with oral cavity cancer is experiencing a
delay in the beginning of his adjuvant therapy. Follow-
ing surgery, he subsequently developed COVID-19
pneumonia. Despite two consecutive swabs detected
no sign of infection, the third one proved to be posi-
tive. Further two consecutive swabs performed recently
demonstrated absence of COVID-19 infection. The
patients are actually scheduled to start postoperative
RT, which will be performed after 71 days from
surgery.
Overall, follow-up consultations were regularly per-
formed until April 19, 2020. Telehealth surveillance sub-
sequently performed for 21 patients. Among these three
patients who had completed their RT course, were sched-
uled for a short-term consultation for a more comprehen-
sive assessment (tracheostomy removal, toxicity
evaluation, and physical assessment of gross tumor
response, respectively).
3.4 | Impact on health professionals
Overall, two health care professionals involved in the
management of HNC patients (a radiation therapist and
a radiation oncology resident, 51 and 33 years old, respec-
tively) were found to be COVID-19 positive at nasal
swabs. Both of them had been in contact with the patient
diagnosed with COVID-19- related pneumonia. They
have no comorbidities and clinical presentation of
COVID-19 infection was mild in both cases (anosmia,
diarrhea, fatigue, and fever). No respiratory symptoms
were reported and hospitalization was therefore not
needed. In compliance with safety measurements, both
of them were re-admitted to work after two consecutive
negative nasal swabs.
Since pregnancy, has been recognized as a risk factor
for developing a COVID-19 related severe acute respira-
tory distress syndrome,19 a radiation oncology resident in
her seventh month of pregnancy was suspended from
clinical practice and was assigned research works she
could manage from home.
4 | DISCUSSION
Radiation treatment management of HNC patients in the
COVID-19 era is challenging. As Lombardy was the first
European area affected form COVID-19 pandemic, guide-
lines, and recommendation for RT in HNC patients were
very limited at that time. Therefore, our department
approved extra-caution measurements to maintain ade-
quate safety standards for both patients and health care
personnel to minimize the risk of transmission. Our expe-
rience has shown that the designation as an oncological
hub, together with internal procedures, allowed preserv-
ing our standard of care while protecting health profes-
sionals treating HNC patients.
As COVID-19 likely binds to epithelial cells in the
nasal cavities and the oropharynx,20 aerosolized droplets
from infected patients determine a high risk of transmis-
sion during the whole HNC clinical workflow, from diag-
nosis (ie, physical examination, trans-oral endoscopy) to
treatment delivery (ie, surgery, RT ± systemic therapy).5
During the emergency, it was difficult to identify a clear
cut between our duty to provide optimal care and the one
to protect health care professional and their families from
infection.5 Specifically, contamination reduction had to
be balanced with the need of guaranteeing access to the
best treatment options, as per national and international
guidelines.6 If an absolute solution to this ethical ques-
tion is probably impossible to be found, the issue has
been debated by some authors. Shuman et al advocate for
a deliberate effort toward balancing exposure and
maintaining moral and professional integrity in patient
care.21
An additional concern for HNC patients who undergo
RT is the counterbalance between the benefit of a timely
delivered treatment and the risk of contracting COVID-
19 infection during the 7 weeks of an average curative-
intent irradiation. In this regard, Bhattacharjee et al
developed a multistate and hazard model to simulate the
risk of death from disease progression vs the risk of death
from COVID-19 infection in patients diagnosed with
stage IV cancer of the oral cavity.22 Given the risks of
hospital admission, the authors suggest to defer treat-
ment in this subset of HNC patients and to make efforts
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to minimize the chance of infection. While statistical
models can provide reasonable solution to practical and
ethical problems in the COVID-19 era, there was an
unmet need for practice recommendations encompassing
different clinical scenarios (ie, curative vs adjuvant treat-
ments, high-risk vs low-risk adjuvant settings). To this
aim, a joint effort by the ASTRO and ESTRO has pro-
duced an expert consensus statement for five common
cases of HN carcinoma.7 While the reader is invited to
refer to the full recommendations, we would like to focus
on the need of adequately prioritizing treatment at the
time of limited resources. Of note, as the authors claim,
all measurements and recommendations need to be
weighted according to the extent and duration of the pan-
demic across nations and regions, which are hardly pre-
dictable and constantly evolving.7 As hospitals represent
critical areas in the epidemiology of the disease, it is
therefore straightforward to understand how critical it is
to keep transmission rates as low as possible in all health
care facilities. The rationale of oncological hubs insti-
tuted in March 2020 is to provide the best treatment
options to the highest number of safely eligible patients,
in order to preserve oncological outcomes of these
populations. Our experience shows that these measures
were effective in limiting cross-infections for candidates
to curative-intent RT for HNC. Overall, we did not expe-
rience a significant reduction in the number of treated
patients, while maintaining high-quality standards for
delivered treatments.
In the context of HNCs, IMRT has proven to be supe-
rior to three-dimensional conformal radiotherapy in
reducing both acute and long-term treatment-related side
effects (ie, xerostomia, dysphagia) without jeopardizing
oncological outcomes.23-25 Coherent with these results,
we decided not to modify our planning strategies and to
prioritize the maintenance of high-quality treatment
standards for our patients. To this aim, set-up accuracy is
an essential condition to ensure a safe and effective treat-
ment delivery. Therefore, in order to assure an accurate
set-up, our immobilization device is provided with a
mouthpiece-assisted bite for every curative-intent treat-
ment. A previous study from our department showed that
using this device maintains the set-up error within 5 mm
in all directions.26 As we did not test the outcomes of
patients' positioning without a mouthpiece-assisted bite,
we favored to maintain our standard immobilization pro-
cedures despite they could not allow patients to wear sur-
gical masks. Accordingly, all radiation therapists
managing HNC patients were considered at high risk of
COVID-19 infection and equipped with personnel protec-
tion accordingly. Therefore, they were instructed to safely
use PPE, as well as to adequately sanitize treatment
rooms and any equipment in contact with patients.
Results of our report highlight that to maintain a high-
quality standard of care, RT for HNC patients requires
adequate personal protection as well as a department
reorganization to optimize the room sanitization.
Considering that a percentage of individuals ranging
from 13% to 30% were found to be COVID-19 asymptom-
atic, all HNC patients were considered as potentially
COVID-19 carriers.6,27 One of the limitations in our man-
agement was the impossibility to perform a swabs-based
screening to all patients prior to the beginning of RT. A
Chinese respective cohort study has underlined that the
correct use of PPE prevented all 41 health care workers
included in the analysis from being infected following
the contact with COVID-19-positive patients.28,29 Despite
higher probability of contact with COVID-19 infected
patients, Lombardy centers received, less PPE than the
Italian average, most probably due to insufficient supply
at the beginning of the outbreak. As an example, FFP2
and FFP3 provisions to the health care personnel were
approximately 2 and 3 times lower in Lombardy than
other regions, respectively.1 Therefore, at our department
during the first weeks of the outbreak, priority for PPE
assignment was given to those managing HNC patients.
Arguably, this strategy probably contributed to reduce
cross-infections between potentially COVID-19 positive
HNC patients and health care providers. The relatively
limited number of COVID-19 cases among health profes-
sionals in our department could therefore be explained
by contacts with asymptomatic carriers before rigorous
self-protection measurements were introduced. Encour-
agingly, no other cases were diagnosed among our Col-
leagues recently. This might suggest that the high risk of
cross-infection of HNC patient's management was miti-
gated by the use of adequate PPE.
We are well aware that further protective measure-
ments could have been taken. Possibly, the risk of viral
dissemination could have been further reduced by defin-
ing two separate working shifts for health care profes-
sionals, as well as by creating separate areas for patients
at higher risk for COVID-19 infection. Serological screen-
ings for the whole staff have been executed only in a
minority of swab-proven cases, while a systematic testing
is programmed for the upcoming weeks. However, at the
time of the outbreak available guidelines and/or recom-
mendation were scares and admittedly, the pandemic
urged us to quickly address unprecedented issues and to
balance patients' and personnel's safety and oncological
indications.
Overall, the peculiarities of our experience derive
from our designation as an oncological hub in an area of
severe COVID-19 outbreak, from the patients' volume
and from the need (especially in the early phases of the
emergency) of optimizing the use PPE. However, our aim
ALTERIO ET AL. 7
is far from being either educational or didactic. The cur-
rent work should in fact be considered as an early report
of our management for HNC patients at the time of an
unprecedented global health crisis. Nevertheless, we
believe that it could be useful to provide our fellow radia-
tion oncologists with a set of indication covering depart-
ment organization in providing patients' and health
professionals protection.
5 | CONCLUSION
We presented the first report analyzing the beginning of
COVID-19 pandemic in Europe with a dedicated focus
on HNC patient's candidate to curative radiation treat-
ments. Results of the present work show that an ade-
quate and well-timed organization (both in terms of
national/regional and Institutional rules) permitted us to
maintain a high-quality RT standard of care, balancing
the best clinical practice with health care personnel's
safety.
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